Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Share News (VAL)

Share Price Information for ValiRx (VAL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.25
Bid: 3.20
Ask: 3.30
Change: 0.00 (0.00%)
Spread: 0.10 (3.125%)
Open: 3.25
High: 3.25
Low: 3.25
Prev. Close: 3.25
VAL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Small caps round-up: Rock Solid, ValiRx, InternetQ, Quindell

Mon, 02nd Apr 2012 13:36

Rock Solid Images, an oil equipment, services and distribution firm, has received an offer from Thalassa Holdings to acquire up to 25.89 per cent of the company for 0.48p per share in cash. Rock Solid is concerned that Thalassa has provided no evidence that they will bring any "added economic or industrial assistance to the business in the next phase of the company's development". With regards to their own shareholdings, the directors do no propose to take up the offer. ValiRx, an AIM-quoted life science company, has conditionally raised £0.9m (before fees and expenses) following a placing of 200m new ordinary shares at a price of 0.45p per share. The proceeds will be used to further along a number of drug trials and expand its intellectual property portfolio and value. Six of the directors purchased a total of more than 10m of the shares. Mobile marketing and digital entertainment services firm InternetQ posted a rise in revenue from €37.3m to €50.1m after a rise in the number of users. Adjusted profit before tax leapt 42.2% from €2.3m to €3.3m, leading to earnings per share of €0.12. Cash and cash equivalents on December 31st was €10.6m, including restricted cash of €0.9m. "Mobile device connections have reached around 5.2bn at the end of 2011. Based on an analysis presented by Google this translates to some 3.7bn unique users. There are just 1.2 bn PCs in use worldwide," the firm said. Quindell Portfolio, a brand extension company, has acquired a further 47.7% of Ai Claims Solutions, an outsourcer for the management of motor claims. The move takes its stake to around 77.6%. The transaction cost the firm 3.1m pounds. As a result, Quindell has made an obligatory mandatory cash offer to acquire the entire issued share capital of Ai Claims not already owned by the Quindell Group. NR
More News
24 Jul 2020 17:23

IN BRIEF: ValiRx Raises GBP300,700 From Broker Option

IN BRIEF: ValiRx Raises GBP300,700 From Broker Option

Read more
23 Jul 2020 18:02

UK TRADING UPDATE SUMMARY: Gear4music Strikes Right Note As Sales Jump

UK TRADING UPDATE SUMMARY: Gear4music Strikes Right Note As Sales Jump

Read more
16 Jul 2020 15:57

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
6 Jul 2020 18:19

IN BRIEF: ValiRx Outlines Oncology, Women's Health Focus

IN BRIEF: ValiRx Outlines Oncology, Women's Health Focus

Read more
6 Jul 2020 09:31

ValiRx looks to build on portfolio of drug candidates

(Sharecast News) - Medicines developer ValiRx said on Monday that it was looking to build on its existing portfolio of drug candidates and grow a pipeline of innovative, early-stage projects in the areas of oncology and women's health.

Read more
1 Jul 2020 13:10

IN BRIEF: ValiRx Annual Loss Narrows As Expenses Fall

IN BRIEF: ValiRx Annual Loss Narrows As Expenses Fall

Read more
16 Jun 2020 13:58

IN BRIEF: ValiRx Cuts Pay By Two Thirds; Terminates GeneICE Agreement

IN BRIEF: ValiRx Cuts Pay By Two Thirds; Terminates GeneICE Agreement

Read more
8 Jun 2020 15:39

ValiRx Delays Annual Results Amid Covid-19 Pandemic

ValiRx Delays Annual Results Amid Covid-19 Pandemic

Read more
2 Jun 2020 12:57

UK TRADING UPDATE SUMMARY: Novacyt Virus Test Orders At EUR135 Million

UK TRADING UPDATE SUMMARY: Novacyt Virus Test Orders At EUR135 Million

Read more
2 Jun 2020 12:03

ValiRx enters collaboration agreement for Covid-19 treatment

(Sharecast News) - Biotechnology oncology company ValiRx has entered into a collaboration agreement with Oncolytika and Black Cat Bio to explore the use of VAL201 in a combination treatment for patients suffering a hyperimmune response to Covid-19.

Read more
29 May 2020 15:02

UK TRADING UPDATE SUMMARY: Catenae Inks Pilot Pact For Cov-ID App

UK TRADING UPDATE SUMMARY: Catenae Inks Pilot Pact For Cov-ID App

Read more
29 May 2020 12:59

ValiRx offloads non-core IP to DDTech

(Sharecast News) - ValiRx has entered into a deed of assignment with Drug Discovery Technologies (DDTech) for the patents, materials and know-how associated with its non-core intellectual property 'FitBio' and 'TRAC', it announced on Friday.

Read more
27 May 2020 14:20

UK EXECUTIVE CHANGE SUMMARY: ValiRx Appoints Biotaspheric CEO As Chair

UK EXECUTIVE CHANGE SUMMARY: ValiRx Appoints Biotaspheric CEO As Chair

Read more
7 May 2020 14:45

UK EXECUTIVE CHANGE SUMMARY: Connect Picks Ex-Synthomer CFO As Chair

UK EXECUTIVE CHANGE SUMMARY: Connect Picks Ex-Synthomer CFO As Chair

Read more
4 May 2020 16:18

REPEAT: ValiRx Completes GBP1.2 Million Placing For Trial Close-Out

REPEAT: ValiRx Completes GBP1.2 Million Placing For Trial Close-Out

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.